ReviewBritish journal of clinical pharmacology2026
Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.
Review in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities.Biomolecules · 2026Review
- Design, Synthesis, In Silico and In Vitro Pharmacological Profiling of Cannabidiol-like Synthetic Analogues as Multi-Target Anti-Alzheimer's Agents.Molecules (Basel, Switzerland) · 2026Article
- Cannabidiol in Dietary Supplements: Characteristics, Routes of Administration, Bioavailability, and Research Challenges.Molecules (Basel, Switzerland) · 2026Review
- Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.British journal of clinical pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia, epilepsy and anxiety. Additionally, cannabinoids are frequently used for recreational purposes. The evolving legislation surrounding cannabis has added a layer of complexity to the understanding of its pharmacological effects. Societal attitudes shifting towards a more permissive acceptance of cannabis use make it essential to balance individual freedom with public health concerns. While the use of cannabinoids remains a subject of ongoing research, clinical data have shown promise in the treatment of mental health disorders. However, debates and concerns have been raised regarding the potential pharmacokinetic (PK) drug-drug interactions that may occur, involving changes in the absorption, distribution, metabolism and excretion (ADME) of the prescribed drugs. The future prospect of patients having unrestricted access to cannabis requires special attention in case of concurrent use with the common medical treatments they may be receiving for a cardiovascular or metabolic disease or with medications related to the treatment of psychiatric disorders. This comprehensive review aims to critically discuss the main PK interactions of major cannabinoids (tetrahydrocannabinol, cannabidiol, cannabinol, cannabichromene and cannabigerol) in relation to the drugs prescribed in neuropathic pain, depression, anxiety, schizophrenia, epilepsy and cancer, as well as with the most common cardiometabolic disease treatments such as statins, beta-blockers, warfarin, insulin analogues and metformin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.